You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2024

DECASPRAY Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Decaspray, and what generic alternatives are available?

Decaspray is a drug marketed by Merck and is included in one NDA.

The generic ingredient in DECASPRAY is dexamethasone. There are thirty-nine drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the dexamethasone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Decaspray

A generic version of DECASPRAY was approved as dexamethasone by KEY THERAP on April 28th, 1983.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DECASPRAY?
  • What are the global sales for DECASPRAY?
  • What is Average Wholesale Price for DECASPRAY?
Drug patent expirations by year for DECASPRAY
Recent Clinical Trials for DECASPRAY

Identify potential brand extensions & 505(b)(2) entrants

Multiple Myeloma Research ConsortiumPhase 2
Millennium Pharmaceuticals, Inc.Phase 2
Washington University School of MedicinePhase 2

See all DECASPRAY clinical trials

US Patents and Regulatory Information for DECASPRAY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck DECASPRAY dexamethasone AEROSOL;TOPICAL 012731-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for DECASPRAY

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
AbbVie Deutschland GmbH & Co. KG Ozurdex dexamethasone EMEA/H/C/001140
Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO).Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis.Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.
Authorised no no no 2010-07-26
THERAVIA Neofordex dexamethasone EMEA/H/C/004071
Treatment of multiple myeloma.
Authorised no no no 2016-03-16
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.